Israel-Based Medical Cannabis Solutions Provider, Kanabo Research, has Signed an Agreement With Constance Therapeutics From the US - Seite 2

of medical cannabis extraction and vaporization solutions. Kanabo's
vaporization device - VapePod - allows patients to inhale natural
cannabis and increase effectiveness without any smoke. Similarly, the
device, which is patent protected, lets patients monitor the dosage
precisely and over time. Kanabo's extraction pods, which are based on
extensive medical trials and in cooperation with leading doctors in
Israel and around the world, provide treatments that target central
nervous system disorders affecting sleep, anxiety and chronic pain.

The company was founded in 2016 by CEO, Avihu Tamir, and COO,
David Sack. Among the partners and investors are David Tsur,
Co-founder and former Chief Executive Officer of Kamada Ltd. (NASDAQ:
KMDA). Dr. Doron Friedman, CTO with over 25 years' experience as a
biomedical entrepreneur and executive. Dr. Friedman is the inventor
of Bausch and Lomb's Lotemax eye drops, and holds over 80 patents.
And Dr. Nachshon Knoler, world-renowned neurosurgeon, currently
Director of the Department of Neurosurgery at Sheba Medical Center in
Tel-Hashomer, Israel.

Kanabo Research operates in the Science Park at Weitzman
Institute. Visit: http://www.kanaboresearch.com/

About Constance Therapeutics

Constance Therapeutics is a vertically-integrated medicinal
cannabis company producing standardized, science-based whole-plant
cannabis extracts. These extracts fill the gap between traditional
pharmaceuticals and commonplace cannabis products, providing much
needed additional treatment options for physicians and their
patients.

Constance Therapeutics' extracts are derived from fully trimmed,
female, unfertilized cannabis flowers of plants with known genetics
using certified organic, pharmaceutical-grade ethanol via a
highly-controlled, quantitatively defined and patented process based
on solid scientific and engineering principles. Extracts are
systematically third-party tested and routinely cross-tested in the
industry's most respected laboratories. Since 2008, the company has
employed stringent, science-based processes and standards to ensure
the highest quality and consistency.

Headquartered in San Francisco, CA, and recently permitted under
the new California regulations, Constance Therapeutics' cannabis
extracts have historically been available exclusively for therapeutic
use by registered California patients under Proposition 215 and
California Senate Bill 420. With the new California regulations, in
addition to continuing to serve their physician referred medical
patients, Constance Therapeutics will distribute their products
throughout the state for sale in licensed dispensaries. Additionally,
Constance Therapeutics is underway with globally licensing their
patented formulations for sale in legal markets across the world. For
further information, visit http://www.constancetherapeutics.com.

ots Originaltext: Constance Therapeutics and Kanabo Research
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Gil Kraiem
[e-mail]
[phone]